← Eichor
Condition: Er Her2 Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Er Her2 Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
Phase 2 · 8 location(s) · Fondazione Oncotech · NCT06259929A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07014410Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT05305924Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patien
Phase 1/Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07235176A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07483307A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06110793NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Phase 3 · 1 location(s) · Peking University · NCT02535221A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · 709 location(s) · AstraZeneca · NCT05774951TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
Phase N/A · 3 location(s) · iOMEDICO AG · NCT07563595Role of the Immune Environment in Response to Therapy in Breast Cancer
Phase N/A · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05396612Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2 · 10 location(s) · Canadian Cancer Trials Group · NCT05601440Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Phase 3 · 109 location(s) · European Organisation for Research and Treatment of Cancer - · NCT05512364Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · 203 location(s) · Celcuity Inc · NCT06757634Capecitabine in ER+/HER2-negative Breast Cancer
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT07631052A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 3 · 2 location(s) · InventisBio Co., Ltd · NCT06954961A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06525766Elacestrant in Advanced Triple Positive Breast Cancer
Phase 1/Phase 2 · 1 location(s) · NYU Langone Health · NCT07612215PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Phase 1 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT04360941A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Phase 2 · 2 location(s) · National Taiwan University Hospital · NCT05766410A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.